
RGLS
Healthcare · Biotechnology · $565.0M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2025
EPS trend, 90 days to now · -7.4% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 12, 2025 | Time not confirmed | -0.21 | 0.00 | +100.0% |
| May 7, 2025 | After the close | -0.27 | -0.15 | +43.4% |
| Mar 19, 2025 | Before the open | -0.22 | -0.20 | +10.1% |
| Nov 7, 2024 | After the close | -0.17 | -0.21 | -23.5% |
| Aug 8, 2024 | After the close | -0.15 | -0.17 | -13.3% |
| May 9, 2024 | After the close | -0.22 | -0.29 | -31.8% |
| Mar 21, 2024 | After the close | -0.39 | -0.40 | -2.6% |
| Nov 9, 2023 | After the close | -0.40 | -0.40 | 0.0% |
| Aug 8, 2023 | After the close | -0.41 | -0.37 | +9.8% |
| May 11, 2023 | After the close | -0.44 | -0.42 | +4.5% |
| Mar 23, 2023 | After the close | -0.51 | -0.40 | +21.6% |
| Nov 10, 2022 | After the close | -0.49 | -0.50 | -2.0% |
| Aug 11, 2022 | After the close | -0.48 | -0.50 |
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective…
| -4.2% |
| May 12, 2022 | After the close | -0.53 | -0.50 | +5.7% |
| Mar 10, 2022 | After the close | -0.67 | -0.70 | -4.5% |
| Nov 10, 2021 | After the close | -0.77 | -1.00 | -29.9% |
| Aug 10, 2021 | After the close | -0.80 | -0.80 | 0.0% |
| May 13, 2021 | After the close | -0.90 | -0.80 | +11.1% |
| Mar 9, 2021 | After the close | -1.40 | -0.30 | +78.6% |
| Nov 5, 2020 | After the close | -2.08 | -0.40 | +80.8% |
| Aug 13, 2020 | After the close | -1.07 | -2.30 | -115.0% |
| May 14, 2020 | After the close | -1.20 | -2.50 | -108.3% |
| Mar 12, 2020 | After the close | -2.40 | -2.30 | +4.2% |
| Nov 12, 2019 | After the close | -2.62 | -2.60 | +0.8% |
| Aug 8, 2019 | After the close | -5.43 | -3.00 | +44.8% |
| May 9, 2019 | After the close | -11.50 | -3.10 | +73.0% |
| Mar 18, 2019 | Before the open | -9.18 | -9.80 | -6.8% |
| Nov 8, 2018 | After the close | -12.52 | -11.80 | +5.8% |
| Aug 9, 2018 | After the close | -18.60 | -15.60 | +16.1% |
| May 10, 2018 | After the close | -17.76 | -18.00 | -1.4% |
| Mar 7, 2018 | After the close | -19.03 | -16.80 | +11.7% |